Drug Profile
IDH 305
Alternative Names: IDH-305Latest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Novartis Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Solid tumours
- No development reported Acute myeloid leukaemia
Most Recent Events
- 30 Mar 2022 Suspended - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in Netherlands, Germany, Spain, Belgium, Australia, Singapore, Canada and USA (PO)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy) in Australia (PO)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Australia (PO)